{"brief_title": "Safety and Efficacy Study of YM087 (Conivaptan) in Patients With Acute Decompensated Heart Failure", "brief_summary": "This is a randomized, double-blind, placebo-controlled, dose ranging pilot study to examine the effects of conivaptan in patients with acute decompensated heart failure.", "condition": ["Chronic Heart Failure"], "intervention_type": ["Drug", "Drug"], "intervention_name": ["conivaptan", "placebo"], "description": ["IV", "IV"], "arm_group_label": ["2", "3", "4", "1"], "other_name": ["Vaprisol", "YM087"], "criteria": "Inclusion Criteria: - Patients may be male or female age 18 years or older. - Women must be post-menopausal or surgically sterile. - Patients must have chronic heart failure of at least 2 months duration and be hospitalized for the treatment of worsening heart failure. The primary manifestation of worsening heart failure must be worsening dyspnea.", "gender": "All", "minimum_age": "18 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "keyword": "YM078", "mesh_term": ["Heart Failure", "Conivaptan"], "id": "NCT00057356"}